1. Medtech Insight
  2. >>Policy & Regulation

Gottlieb Takes To Twitter To Raise FDA Morale Amid Shutdown

Over the past few days US FDA Commissioner Scott Gottlieb has been tweeting about the ongoing government shutdown, including offering his appreciation of agency staffers working under the government shutdown and his support to staffers who have been furloughed. While the agency is operating with carryover user-fee money, the shutdown has limited the agency’s ability to review new products and develop policies.

FDA commissioner Scott Gottlieb
Scott Gottlieb

US FDA Commissioner Scott Gottlieb has taken to Twitter in recent days to thank agency staff who are still working under the ongoing government shutdown and offered words of support to those who’ve been furloughed. Almost half of CDRH’s staff have been furloughed since Dec. 22 when President Trump and Congress couldn’t agree on a budget to keep the government running.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Congress, Researchers Highlight Security Risks At DNA Testing Services

 
• By Elizabeth Orr

Congress has launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.

Notified Bodies Warn Of Hurdles In The Way Of Their AI Designations

 
• By Amanda Maxwell

Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?

Guidance Feedback Highlights Outstanding Questions In AI Development

 
• By Elizabeth Orr

Many of the hundred-plus commenters to the FDA's draft guidance on AI in medical product regulation said the document was a good start but needed additional clarity and more concrete examples. Stakeholders recommended the inclusion of case studies, metrics, and clearer guidelines to enhance the utility of the guidance, which is seen as a vital step for AI integration in healthcare.